|
Oct 9
|
Cardiol Therapeutics Announces Pricing of Public Offering of Common Shares
|
|
Oct 8
|
Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares
|
|
Jun 27
|
Cardiol Therapeutics Reports Results of 2024 Annual General and Special Meeting of Shareholders
|
|
Jun 25
|
Cardiol Therapeutics to Webcast Virtual Annual General and Special Meeting of Shareholders on June 26th at 4:30 p.m. EDT
|
|
Jun 13
|
Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
|
|
May 14
|
Cardiol Therapeutics Announces Phase II ARCHER Trial Presented at the World Congress on Acute Heart Failure 2024
|
|
Apr 2
|
Cardiol Therapeutics Announces Year-End 2023 Update on Operations
|
|
Jan 9
|
Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis
|
|
Dec 5
|
Cardiol Therapeutics Announces Massachusetts General Hospital, Largest Teaching Hospital of Harvard Medical School, as the 8th Major Medical Centre Participating in MAvERIC-Pilot
|
|
Oct 20
|
Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
|
|
Jun 29
|
Cardiol Therapeutics Reports Results of 2023 Annual General Meeting
|
|
Jun 27
|
Cardiol Therapeutics to Webcast Virtual Annual General Meeting on June 28th at 4:30 p.m. EDT
|